Completed PHASE2 INTERVENTIONAL 3-arm NCT00491985

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions Influenza Influenza A Virus Infection Orthomyxoviridae Infections

Interventions A/H5N1 Inactivated, split virion pandemic influenza vaccine A/H5N1 Inactivated, split-virion pandemic influenza vaccine

Updated 5 times since 2017 Last updated: Jan 10, 2014 Started: Jun 30, 2007 Primary completion: Dec 31, 2009 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Influenza and Influenza A Virus Infection and is currently completed. Sanofi Pasteur, a Sanofi Company leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi Pasteur, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangkok, Thailand